California Attorney Says DEA Rescheduling Keeps LA Cannabis Appeal Alive

Attorney Invokes DEA Rescheduling to Preserve Appeal

A California attorney argued in federal court that the DEA's ongoing rescheduling process prevents dismissal of a Los Angeles cannabis appeal. Law360 reported the filing on May 26, 2026. It contends that moving cannabis to Schedule III under the Controlled Substances Act would fundamentally alter the legal framework governing the case. The attorney didn't identify the specific case or parties in the public report, but the procedural posture suggests the appeal involves either licensing disputes or enforcement actions tied to cannabis's current Schedule I status.

The DEA's rescheduling notice of proposed rulemaking (NPRM) was published in May 2024, triggering a public comment period that closed in July 2024. The agency hasn't yet issued a final rule. Federal courts routinely stay or dismiss cases when regulatory changes are imminent, but attorneys can argue that pending rules preserve live controversies if the outcome remains uncertain.

Schedule III Status Would Reshape Legal Landscape

Rescheduling cannabis to Schedule III would eliminate the strictest federal prohibitions but leave state-licensed operators in a regulatory gray zone. Schedule III drugs—such as ketamine and anabolic steroids—can be prescribed and are subject to less stringent manufacturing and distribution controls than Schedule I substances. Still, Schedule III drugs remain federally controlled. State-licensed cannabis businesses would still operate in violation of the Controlled Substances Act absent further congressional action.

Pending litigation faces significant legal implications. Cases challenging DEA enforcement actions, FDA jurisdiction, or IRS Section 280E tax treatment could gain new arguments under Schedule III. Some plaintiffs could lose standing if rescheduling moots their claims. The California attorney's filing appears to thread this needle by arguing that the appeal's core issues—likely related to Los Angeles municipal licensing or zoning—remain live regardless of federal scheduling.

Los Angeles Cannabis Operators Face Layered Compliance Burden

Los Angeles cannabis businesses must satisfy overlapping city, state, and federal rules, making litigation outcomes highly sensitive to regulatory shifts. The city's Department of Cannabis Regulation (DCR) oversees local licensing, while California's Department of Cannabis Control (DCC) enforces statewide standards. Federal rescheduling wouldn't change state law but could influence how courts interpret preemption arguments or federal-question jurisdiction in local disputes.

Los Angeles has issued approximately 400 retail licenses and 200 cultivation licenses since adult-use sales began in 2018. Operators have challenged DCR decisions on license denials, equity-program eligibility, and zoning restrictions. If the pending appeal involves a DCR decision, the attorney's rescheduling argument may be designed to preserve claims that federal Schedule I status unfairly influenced the city's regulatory posture.

Federal Courts Split on Mootness in Cannabis Cases

Federal appellate courts have issued conflicting rulings on whether pending regulatory changes moot cannabis litigation. In 2023, the Ninth Circuit held that California's legalization of adult-use cannabis didn't moot a challenge to federal asset forfeiture, reasoning that the plaintiff retained a concrete interest in recovering seized property. By contrast, the Fifth Circuit dismissed a Texas hemp case in 2024 after the USDA finalized new THC testing rules, finding that the new regulations rendered the plaintiff's claims hypothetical.

The California attorney's argument likely relies on the Ninth Circuit's narrower mootness standard. The court may find that rescheduling doesn't eliminate the case or controversy if the appeal involves a constitutional challenge or a claim for damages rather than prospective relief. Timing matters here. If the rule is published before the court rules on the motion to dismiss, the attorney's argument becomes stronger.

280E Tax Relief Hinges on Final Rule Publication

Cannabis operators currently face effective tax rates exceeding 70 percent under IRS Section 280E, which disallows business deductions for Schedule I and II substances. Rescheduling to Schedule III would eliminate 280E liability, saving the industry an estimated $1.8 billion annually, according to a 2024 analysis by cannabis tax firm Viridian Sciences. The relief isn't retroactive. Operators can't amend prior-year returns unless the final rule explicitly grants retroactive effect or a court orders it.

If the Los Angeles appeal involves a 280E challenge or a related tax dispute, the attorney's filing may be positioning the case to survive until the final rule is published. Courts have discretion to stay proceedings pending agency action, but they aren't required to do so if the case presents live issues independent of the rulemaking. The attorney's strategy appears designed to avoid voluntary dismissal while preserving the option to amend claims once the DEA acts.

What the Filing Signals About DEA Timeline

The attorney's invocation of rescheduling suggests expectations that the DEA will publish a final rule within the appeal's litigation window. The DEA hasn't announced a target date for the final rule, but administrative law experts estimate publication in late 2026 or early 2027 based on the agency's historical rulemaking timelines. The NPRM drew more than 43,000 public comments—the most in DEA history—requiring extensive staff review and response.

The filing reflects a calculated bet that the DEA will act before the court issues a final ruling, preserving the appellant's ability to argue that rescheduling changes the case's legal foundation.

If the DEA delays the final rule beyond 2027, the court may proceed to rule on the merits under current Schedule I law, potentially rendering the rescheduling argument moot. If the rule is published imminently, the court may grant a stay or allow supplemental briefing to address the new regulatory framework.

Broader Implications for Cannabis Litigation Strategy

The California filing illustrates how attorneys are using the DEA's rescheduling process as a procedural tool to keep cases alive and preserve future remedies. Similar arguments have appeared in at least six federal cases since the NPRM was published, according to a CannIntel review of PACER filings. Plaintiffs in tax disputes, licensing challenges, and criminal appeals have all invoked rescheduling to argue against dismissal or summary judgment.

The strategy carries risks. Courts may view rescheduling arguments as speculative or dilatory if the final rule is significantly delayed. Also, if the DEA's final rule includes provisions that undercut the plaintiff's legal theory—such as maintaining federal enforcement discretion or imposing new Schedule III compliance costs—the argument could backfire. For full background on this story, see the CannIntel topic hub on DEA rescheduling.

The next major signal will be the DEA's publication of the final rule or any interim guidance on how pending litigation should be treated during the rulemaking process. Until then, attorneys on both sides will continue to litigate under Schedule I law while positioning for a post-rescheduling environment.